VentureBeat September 24, 2024
Louis Columbus

With all seven independent directors resigning from 23andMe last week, the company has become a cautionary tale of why cybersecurity is a business decision for any enterprise first, as there are immediate and lasting impacts to any organization ignoring that. Customers aren’t sure how the company plans to strengthen its security and protect their DNA and other confidential personally identifiable information (PII). Enterprises can’t afford to allow security to become a liability.

Multiple large-scale security breaches have jilted existing customers’ confidence and made potential customers think twice about sharing their DNA data with 23andMe.

The independent board members unanimously resigned in response to CEO Anne Wojcicki’s push to take the company private on Sept. 17. The resignation states that they...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Cybersecurity, Pharma / Biotech, Technology
STAT+: 3 trends to watch in biotech in 2025
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease

Share This Article